Close Menu

NEW YORK (GenomeWeb) – Despite setbacks in recent years, diagnostics firm Epigenomics continues to push for clinical adoption and reimbursement of its colorectal cancer screening test Epi proColon, hoping to cement its position in the blood-based detection market at a time when a number of new companies have begun to stake claims but few have yet proved their technologies in the clinic.

Among recent milestones, the firm has launched a kit version of the epigenomic test technology behind Epi proColon, announcing the product last month.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.

Dec
11
Sponsored by
Roche

This webinar will address how two molecular laboratories are implementing tertiary analysis software to improve their precision oncology workflows.

Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.